Novacyt Aktie

Novacyt PEG

PEG-forhold (Pris/Indtjening-til-vækst) for Novacyt (ALNOV.PA) pr. 24. aug. 2026.

PEG

0,00

Senest opdateret:

PEG-forhold (Pris/Indtjening-til-vækst) for Novacyt er 2026 0,00 . PEG-forhold (Pris/Indtjening-til-vækst) for Novacyt var 2025 0,00 . Det falder dermed med % lavere sammenlignet med året før.

Novacyt PEG historik

Novacyt PEG historik
ÅRPEGYoY
0,00
Access this data via the Eulerpool API

Novacyt Aktieanalyse

Hvad laver Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Novacyt aktie

På Eulerpool kan du finde den fuldstændige historiske udvikling af PEG-forhold (Pris/Indtjening-til-vækst) Novacyt siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

PEG-forholdet justerer P/E-forholdet for den forventede vækstrate i indtjeningen. Et PEG under 1 kan indikere en undervurderet aktie i forhold til dets vækstpotentiale.

PEG = K/G-forhold / Forventet årlig EPS-vækstrate

For at evaluere PEG-forhold (Pris/Indtjening-til-vækst)s er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for PEG-forhold (Pris/Indtjening-til-vækst).

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne PEG-forhold (Pris/Indtjening-til-vækst)s Novacyt med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

Access this data via the Eulerpool API

Værdiansættelse — Novacyt

Alle nøgletal — Novacyt